Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FUUJIN study of durvalumab plus BCG in high-risk non-muscle-invasive bladder cancer
jRCT1030260571Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Oct 2026
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of durvalumab and bcg vaccine in non-muscle-invasive bladder cancer (NMIBC), sponsored by AstraZeneca. Primary endpoint: Real-world disease-free survival. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
durvalumabbcg vaccine
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on jRCT1030260571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1030260571.